BY
Schwartz Biomedical subsidiary BioPoly this week registered for a $5 million Series D round for its joint resurfacing technology.
The BioPoly material combines hyaluronic acid, a naturally occurring lubricant found in joint synovial fluid, and ultra-high-molecular-weight polyethylene, a biocompatible polymer. It’s designed to be used during arthroplasty procedures and won CE Mark approval in the European Union in June 2011.
